Drug Trial Radar · NCT07323654
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
Jan 28, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Kymera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Conditions
- Eosinophilic Asthma
Interventions
KT-621Drug
Oral drug
PlaceboOther
Oral placebo matched to KT-621
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pre-bronchodilator FEV1Time frame: From baseline to Week 12
Locations
81 sites in 13 countries. Site status is shown where the registry gives one.
Kymera Investigative Site
Lancaster, California · Recruiting
Kymera Investigative Site
Long Beach, California · Recruiting
Kymera Investigative Site
Northridge, California · Recruiting
Kymera Investigative Site
Redding, California · Recruiting
Kymera Investigative Site
San Francisco, California · Recruiting
Kymera Investigative Site
Upland, California · Recruiting
Kymera Investigative Site
Aurora, Colorado · Recruiting
Kymera Investigative Site
New Haven, Connecticut · Recruiting
Kymera Investigative Site
Loxahatchee Groves, Florida · Recruiting
Kymera Investigative Site
Miami, Florida · Recruiting
Kymera Investigative Site
Miami, Florida · Recruiting
Kymera Investigative Site
Miami Lakes, Florida · Recruiting
Kymera Investigative Site
Orlando, Florida · Recruiting
Kymera Investigative Site
Tampa, Florida · Recruiting
Kymera Investigative Site
East Point, Georgia · Recruiting
Kymera Investigative Site
Iowa City, Iowa · Recruiting
Kymera Investigative Site
Kansas City, Kansas · Recruiting
Kymera Investigative Site
Louisville, Kentucky · Recruiting
Kymera Investigative Site
Boston, Massachusetts · Recruiting
Kymera Investigative Site
Chapel Hill, North Carolina · Recruiting
Kymera Investigative Site
Durham, North Carolina · Recruiting
Kymera Investigative Site
Toledo, Ohio · Recruiting
Kymera Investigative Site
Edmond, Oklahoma · Recruiting
Kymera Investigative Site
Clackamas, Oregon · Recruiting
Kymera Investigative Site
Philadelphia, Pennsylvania · Recruiting
Kymera Investigative Site
Pittsburgh, Pennsylvania · Recruiting
Kymera Investigative Site
Pittsburgh, Pennsylvania · Recruiting
Kymera Investigative Site
North Charleston, South Carolina · Recruiting
Kymera Investigative Site
Rock Hill, South Carolina · Recruiting
Kymera Investigative Site
Chattanooga, Tennessee · Recruiting
Kymera Investigative Site
Dallas, Texas · Recruiting
Kymera Investigative Site
Dallas, Texas · Recruiting
Kymera Investigative Site
McKinney, Texas · Recruiting
Kymera Investigative Site
Madison, Wisconsin · Recruiting
Kymera Investigative Site
Buenos Aires, Argentina · Recruiting
Kymera Investigative Site
Concepción del Uruguay, Argentina · Recruiting
Kymera Investigative Site
Lobos, Argentina · Recruiting
Kymera Investigative Site
Mar del Plata, Argentina · Recruiting
Kymera Investigative Site
Quilmes, Argentina · Recruiting
Kymera Investigative Site
Rosario, Argentina · Recruiting
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.